Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, et al. Califf RM, et al. Among authors: topol ej. Circulation. 1991 May;83(5):1543-56. doi: 10.1161/01.cir.83.5.1543. Circulation. 1991. PMID: 1902405 Clinical Trial.
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
Califf RM, Topol EJ, George BS, Boswick JM, Lee KL, Stump D, Dillon J, Abbottsmith C, Candela RJ, Kereiakes DJ, et al. Califf RM, et al. Among authors: topol ej. Circulation. 1988 May;77(5):1090-9. doi: 10.1161/01.cir.77.5.1090. Circulation. 1988. PMID: 2966016 Clinical Trial.
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. Ohman EM, et al. Among authors: topol ej. Circulation. 1997 Feb 18;95(4):846-54. doi: 10.1161/01.cir.95.4.846. Circulation. 1997. PMID: 9054741 Clinical Trial.
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ. Berger PB, et al. Among authors: topol ej. Circulation. 1997 Jul 1;96(1):122-7. doi: 10.1161/01.cir.96.1.122. Circulation. 1997. PMID: 9236426 Clinical Trial.
Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group.
Ellis SG, Mooney MR, George BS, da Silva EE, Talley JD, Flanagan WH, Topol EJ. Ellis SG, et al. Among authors: topol ej. Circulation. 1992 Nov;86(5):1400-6. doi: 10.1161/01.cir.86.5.1400. Circulation. 1992. PMID: 1423952 Clinical Trial.
1,218 results